Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEB NASDAQ:CGC NASDAQ:CTMX NASDAQ:CTNM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$2.37+17.9%$2.37$0.80▼$3.42$97.37M-0.89125,346 shs1.00 million shsCGCCanopy Growth$1.37-1.4%$1.29$0.77▼$5.80$328.59M0.7622.03 million shs14.76 million shsCTMXCytomX Therapeutics$2.00-4.3%$2.20$0.40▼$3.10$329.83M2.182.62 million shs1.70 million shsCTNMContineum Therapeutics$12.35+4.6%$7.48$3.35▼$20.30$346.46M1.13277,997 shs198,551 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals0.00%-0.42%-2.87%+70.50%+33.90%CGCCanopy Growth0.00%-6.16%-8.05%-7.43%-70.91%CTMXCytomX Therapeutics0.00%-12.28%+13.64%-27.27%+52.67%CTNMContineum Therapeutics0.00%+7.39%+70.11%+178.78%-31.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$2.37+17.9%$2.37$0.80▼$3.42$97.37M-0.89125,346 shs1.00 million shsCGCCanopy Growth$1.37-1.4%$1.29$0.77▼$5.80$328.59M0.7622.03 million shs14.76 million shsCTMXCytomX Therapeutics$2.00-4.3%$2.20$0.40▼$3.10$329.83M2.182.62 million shs1.70 million shsCTNMContineum Therapeutics$12.35+4.6%$7.48$3.35▼$20.30$346.46M1.13277,997 shs198,551 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals0.00%-0.42%-2.87%+70.50%+33.90%CGCCanopy Growth0.00%-6.16%-8.05%-7.43%-70.91%CTMXCytomX Therapeutics0.00%-12.28%+13.64%-27.27%+52.67%CTNMContineum Therapeutics0.00%+7.39%+70.11%+178.78%-31.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 2.50Moderate Buy$5.50132.07% UpsideCGCCanopy Growth 1.33SellN/AN/ACTMXCytomX Therapeutics 3.00Buy$5.75187.50% UpsideCTNMContineum Therapeutics 3.17Buy$22.7584.21% UpsideCurrent Analyst Ratings BreakdownLatest ANEB, CTMX, CTNM, and CGC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025CTNMContineum TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$20.00 ➝ $21.008/12/2025CGCCanopy GrowthZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/31/2025CTMXCytomX TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.007/23/2025ANEBAnebulo PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/20/2025CTNMContineum TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.15 per shareN/ACGCCanopy Growth$225.65M1.46N/AN/A$1.90 per share0.72CTMXCytomX Therapeutics$138.10M2.39$0.36 per share5.53($0.01) per share-200.00CTNMContineum Therapeutics$50M6.93N/AN/A$7.66 per share1.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.20M-$0.26N/A∞N/AN/A-90.11%-84.53%9/24/2025 (Estimated)CGCCanopy Growth-$429.86M-$3.03N/AN/AN/A-155.76%-89.93%-44.24%11/14/2025 (Estimated)CTMXCytomX Therapeutics$31.87M$0.563.57N/AN/A34.04%158.70%36.04%11/6/2025 (Estimated)CTNMContineum Therapeutics-$42.26M-$2.200.00N/AN/AN/A-29.75%-28.08%11/5/2025 (Estimated)Latest ANEB, CTMX, CTNM, and CGC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/24/2025Q4 2025ANEBAnebulo Pharmaceuticals-$0.05N/AN/AN/AN/AN/A8/8/2025Q1 2026CGCCanopy Growth-$0.15-$0.14+$0.01-$0.16$64.98 million$52.98 million8/5/2025Q2 2025CTNMContineum Therapeutics-$0.56-$0.62-$0.06-$0.62$7.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/ACGCCanopy GrowthN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/ACTNMContineum TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A25.2925.29CGCCanopy Growth0.593.072.12CTMXCytomX TherapeuticsN/A4.204.20CTNMContineum TherapeuticsN/A24.5124.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%CGCCanopy Growth3.33%CTMXCytomX Therapeutics67.77%CTNMContineum TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%CGCCanopy Growth0.16%CTMXCytomX Therapeutics6.60%CTNMContineum Therapeutics11.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals441.08 million7.97 millionNot OptionableCGCCanopy Growth3,150239.85 million239.47 millionOptionableCTMXCytomX Therapeutics170164.91 million154.03 millionOptionableCTNMContineum Therapeutics3128.04 million24.87 millionN/AANEB, CTMX, CTNM, and CGC HeadlinesRecent News About These CompaniesContineum Therapeutics, Inc. (NASDAQ:CTNM) Short Interest Up 63.5% in AugustSeptember 8, 2025 | marketbeat.comBrokerages Set Contineum Therapeutics, Inc. (NASDAQ:CTNM) Target Price at $22.75September 6, 2025 | americanbankingnews.comADAR1 Capital Management LLC Has $1.18 Million Holdings in Contineum Therapeutics, Inc. $CTNMSeptember 4, 2025 | marketbeat.comContineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Average Rating of "Buy" from AnalystsSeptember 4, 2025 | marketbeat.comContineum Therapeutics to Present at September Investor ConferencesAugust 28, 2025 | businesswire.comContineum Therapeutics, Inc. (NASDAQ:CTNM) Short Interest UpdateAugust 21, 2025 | marketbeat.comPositive week for Contineum Therapeutics, Inc. (NASDAQ:CTNM) institutional investors who lost 47% over the past yearAugust 20, 2025 | finance.yahoo.comContineum Therapeutics (NASDAQ:CTNM) Stock Price Expected to Rise, Morgan Stanley Analyst SaysAugust 20, 2025 | marketbeat.comAnalysts Offer Insights on NA Companies: Contineum Therapeutics, Inc. Class A (CTNM) and BrightSpring Health Services, Inc. (BTSG)August 17, 2025 | theglobeandmail.comContineum Therapeutics Reports Q2 2025 Results and Clinical ProgressAugust 13, 2025 | tipranks.comWall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 235.81%: Read This Before Placing a BetAugust 8, 2025 | zacks.comContineum (CTNM) Q2 R&D Jumps 78%August 5, 2025 | fool.comContineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development MilestonesAugust 5, 2025 | businesswire.comContineum Therapeutics Inc. (CTNM) Stock Price Today - WSJAugust 1, 2025 | wsj.comContineum Therapeutics stock falls after trial data delayJune 25, 2025 | investing.comContineum Therapeutics Shares Drop After Delay in Trial Data ReleaseJune 25, 2025 | msn.comContineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791June 25, 2025 | businesswire.comContineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare ConferenceMay 15, 2025 | businesswire.comContineum Therapeutics Reports Q1 2025 Financial ResultsMay 14, 2025 | tipranks.comContineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development MilestonesMay 14, 2025 | businesswire.comWhy Contineum Therapeutics, Inc.’s (CTNM) Stock Is Down 5.54%May 7, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeANEB, CTMX, CTNM, and CGC Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$2.37 +0.36 (+17.91%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.34 -0.03 (-1.27%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Canopy Growth NASDAQ:CGC$1.37 -0.02 (-1.44%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.37 +0.00 (+0.07%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.CytomX Therapeutics NASDAQ:CTMX$2.00 -0.09 (-4.31%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.04 +0.04 (+2.00%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Contineum Therapeutics NASDAQ:CTNM$12.35 +0.54 (+4.57%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$12.58 +0.23 (+1.85%) As of 09/12/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
